Diseases of the Endocrine System | Genetics - Adult, Phase I-II

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)

Volunteers
Health Professionals

What is the purpose of this trial?

The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

Trial with
Vivet Therapeutics, SAS
Ages
18 years - 60 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Daksshi Hettiarachchi

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Michael Schilsky, MD
Professor of Medicine; Medical Director, Adult Liver Transplant, Yale New Haven Transplantation Center

Sub-Investigators

Last Updated
07/19/2024
Study HIC
#2000028887